Kyowa Hakko Kirin's Parkinson's therapy, Nourianz (istradefylline), gains FDA approval as an add-on to levodopa/carbidopa.
News
-
September 02, 2019
-
August 29, 2019
Radicut/Radicava (edaravone), shown to slow the progression of ALS, is now approved for patients in China.
-
August 16, 2019
Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.
-
August 15, 2019
Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.
-
MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses.
-
New skin cancer medicine now approved in the EU for adults with metastatic or locally advanced cutaneous squamous cell carcinoma.
-
June 14, 2019
Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.
-
Vyndaqel (tafamidis) is now approved in the U.S. after study showed increased survivorship rate and reduced hospital time due to heart related problems.
-
April 24, 2019
Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.
-
February 28, 2019
Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years.
-
February 25, 2019
A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.
-
February 07, 2019
The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).
-
February 07, 2019
CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).
-
February 05, 2019
Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.
-
January 30, 2019
Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).
-
January 30, 2019
After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.
-
January 18, 2019
Over 50 countries have approved Spinraza (nusinersen), but not all have made it available to the patients who need it.
-
January 14, 2019
New medicine shows statistically significant improvements for prostate cancer patients.
-
December 20, 2018
A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.
-
December 17, 2018
Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.
-
December 14, 2018
Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).
-
December 03, 2018
Australia provides reimbursement for cystic fibrosis medicine.
-
November 30, 2018
The European Commission has approved Alunbrig (brigatinib) for the treatment of a specific type of lung cancer.
-
November 29, 2018
A late-stage study testing Bavencio (avelumab) has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.
-
November 29, 2018
In an exploratory study Ocrevus (ocrelizumab) slowed down loss of function in the upper extremities for patients with primary progressive multiple sclerosis (PPMS).
-
October 03, 2018
-
September 17, 2018
How two professors imagine a better world for stakeholders in the medical industry.
-
September 17, 2018
"These results offer a leap in understanding about this disease that provides a genetically based framework for designing clinical trials to develop more effective treatments of MPAL,"
-
September 17, 2018
"In short, it will help produce drugs where we can be far more confident about where modifications are being made, so that side effects can be minimized in the future"
-
August 31, 2018
Researchers report a successful classification of triple breast cancer patients, which for the first time, would allow doctors to discern between those who can be cured and those who might suffer a relapse.